Lantern Pharma Inc.
LTRNCIK 0001763950 · Every Form 4 filed by insiders at this issuer. See financials →
Annual report (10-K)
Latest 10-K/A filed Apr 30, 2026. Sentiment + YoY language diff vs prior year. Read sections →
Signal:NeutralFull-doc fallback
Full filing:tone 0.0017
Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.
Recent 8-K announcements
Per-item disclosure feed. Item 2.02 is the earnings release.
Top insiders
Most active reporters at Lantern Pharma Inc.
| Name | Roles | Filings |
|---|---|---|
| Bios Fund II Qp, LP | 10% Owner | 7 |
| Bios Fund II, LP | 10% Owner | 7 |
| Bp Directors, LP | 10% Owner | 7 |
| Bios Equity Partners II, LP | 10% Owner | 7 |
| Keyser D Jeffrey | Director | 5 |
Top performers
Insiders ranked by realized 90-day signed return on their open-market trades at Lantern Pharma Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.
| # | Insider | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|
| 1 | Bios Advisors Gp, LLC | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 2 | Bios Capital Management, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 3 | Bios Fund I Qp, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 4 | Bios Fund I, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 5 | Bios Fund II Nt, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 6 | Bios Fund II Qp, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 7 | Bios Fund II, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 8 | Bp Directors, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 9 | Bios Equity Partners II, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
| 10 | Bios Equity Partners, LP | 55 | 11% | -26.1% | -24.9% | +32.7% | -60.9% |
All filings
39 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|